| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/13/2004 | US6677362 Blending water insoluble drug with solvent-free polyvinylpyrrolidone carrier; dissolving nonionic surfactant and plasticizer; spraying; milling extrudate to powdery mass |
| 01/13/2004 | US6677361 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| 01/13/2004 | US6677346 Methods comprising intranasal morphine |
| 01/13/2004 | US6677342 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 01/13/2004 | US6677327 Food comprising water soluble protein and lecithin; oil-free |
| 01/13/2004 | US6677320 Mixture with chelate compound; bone disorders |
| 01/13/2004 | US6677313 Method for gene therapy using nucleic acid loaded polymeric microparticles |
| 01/13/2004 | US6677304 Ophthalmic formulations |
| 01/13/2004 | US6677301 Epithelial cell proliferation stimulants; wound healing agents |
| 01/13/2004 | US6677164 Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds |
| 01/13/2004 | US6677136 Glucagon antagonist domain, preferably having very little or no glucagon agonist activity, yeast-based screening phage display, rna- peptide screening, etc. attached to a vehicle, e.g., an fc domain, peg or dextran |
| 01/13/2004 | US6676970 Subcutaneous osteoporosis compositions |
| 01/13/2004 | US6676963 Ligand-targeted emulsions carrying bioactive agents |
| 01/13/2004 | US6676962 Patch having elastic backing layer inert to active substance and self adhesive matrix of drug, metal crosslinked poly-acrylate adhesive and fatty acid |
| 01/13/2004 | US6676959 Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption |
| 01/13/2004 | US6676958 Adjuvant composition for mucosal and injection delivered vaccines |
| 01/13/2004 | US6676956 Oil-in-water emulsion for protecting human organs against peroxidation |
| 01/13/2004 | US6676946 Dendrimeric polylysine having bonded epitopes; cancer immuno-therapy |
| 01/13/2004 | US6676941 For inhibiting angiogenesis and induce tumor regression; cancer therapy |
| 01/13/2004 | US6676938 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group B streptococcal carbohydrates |
| 01/13/2004 | US6676935 Transfection target cells; genetic engineering |
| 01/13/2004 | US6676930 Administering dose of mixture of lipid crystals comprising surfactant and spreading agnet as aerosol through an external airway of a mammal for enhancing mammalian eustachian tube lumen patency and pressure equalization performance |
| 01/13/2004 | US6676924 CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| 01/13/2004 | CA2242224C Sustained-release microgranules containing diltiazem as the active principle |
| 01/13/2004 | CA2102630C Pharmaceutical compositions of compacted medicaments |
| 01/08/2004 | WO2004003188A2 Stabilization of granules |
| 01/08/2004 | WO2004003145A2 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/08/2004 | WO2004002566A1 Transdermal drug delivery devices having coated microprotrusions |
| 01/08/2004 | WO2004002559A1 Method and packaging for pressurized containers |
| 01/08/2004 | WO2004002534A1 Use of dimethyl sulfone as isotonicity agent |
| 01/08/2004 | WO2004002533A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | WO2004002528A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | WO2004002468A1 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 01/08/2004 | WO2004002466A1 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| 01/08/2004 | WO2004002459A1 Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
| 01/08/2004 | WO2004002457A2 Conjugates comprising an nsaid and a sugar and uses thereof |
| 01/08/2004 | WO2004002456A1 Biodegradable block copolymeric compositions for drug delivery |
| 01/08/2004 | WO2004002455A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 01/08/2004 | WO2004002454A1 Camptothecin-carboxylate formulations |
| 01/08/2004 | WO2004002453A1 Method and apparatus for producing liposomes |
| 01/08/2004 | WO2004002452A1 Drug composition |
| 01/08/2004 | WO2004002450A1 Coating suspensions (comprising osmopolymers, osmagents) for forming an expandable osmotic composition in controlled release dosage forms as well as the corresponding method for providing this osmotic coating |
| 01/08/2004 | WO2004002449A1 Controlled release of anti-arrhythmic agents |
| 01/08/2004 | WO2004002448A1 Oral dosage from comprising a liquid active agent formulation andcontrolling release thereof by an expandable osmotic composition |
| 01/08/2004 | WO2004002447A2 Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton |
| 01/08/2004 | WO2004002444A2 A platform for transdermal formulations (ptf) |
| 01/08/2004 | WO2004002436A1 Biliquid foam entrapment |
| 01/08/2004 | WO2004002424A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2004002423A2 Cartilage enhancing food supplements with sucralose and methods of preparing the same |
| 01/08/2004 | WO2004002416A2 Methods and materials for treating human papillomavirus infections |
| 01/08/2004 | WO2004002404A2 Compositions and method for enhanced mucosal delivery of interferon beta |
| 01/08/2004 | WO2004002402A2 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 01/08/2004 | WO2004002398A2 Spherical pellet containing a water-soluble active ingredient |
| 01/08/2004 | WO2003093315A3 Specific antibody fragments for the human carcinoembryonic antigen (cea) |
| 01/08/2004 | WO2003092647A3 Transport system in biological systems |
| 01/08/2004 | WO2003091387A3 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 01/08/2004 | WO2003085093A3 Antibodies that specifically bind to gmad |
| 01/08/2004 | WO2003080665A3 Antibody that binds to a dimer of a prion protein for the treatment of tse infection |
| 01/08/2004 | WO2003080032A3 Pharmaceutical formulation for the active ingredient budesonide |
| 01/08/2004 | WO2003077953A3 Bacteriophage composition |
| 01/08/2004 | WO2003066205A3 Microcapsules having high carotenoid content |
| 01/08/2004 | WO2003045965A3 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/08/2004 | WO2003039382A3 System for processing tissue |
| 01/08/2004 | WO2003020876A3 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 01/08/2004 | WO2002099036A3 Inhibition of neurodegeneration |
| 01/08/2004 | WO2002092075A3 Therapeutic delivery of carbon monoxide |
| 01/08/2004 | WO2002091996A3 Methods for treating cancer |
| 01/08/2004 | WO2002053130A3 Sustained release drug delivery devices with coated drug cores |
| 01/08/2004 | WO2001079524A3 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 01/08/2004 | US20040006203 Method for sequential support-bound synthesis of conjugated oligomeric compounds |
| 01/08/2004 | US20040006177 Aggregate-forming agent |
| 01/08/2004 | US20040006111 Transmucosal delivery of proton pump inhibitors |
| 01/08/2004 | US20040006049 For therapy of prostatitis, benign prostate hyperplasia or prostate cancer |
| 01/08/2004 | US20040006045 Methods for the treatment or prophylaxis of disease by inhibition of ornithine decarboxylase |
| 01/08/2004 | US20040006041 Ready-to-use, injectable; stability |
| 01/08/2004 | US20040006010 Compositions include a polynucleotide that is linked to an immunomodulatory molecule, which molecule comprises an antigen and may further comprise immunomodulators such as cytokines and adjuvants. The polynucleotide portion of the |
| 01/08/2004 | US20040006009 Pharmaceutical compositions comprising mannose binding lectin |
| 01/08/2004 | US20040006008 Localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper |
| 01/08/2004 | US20040005999 Sustained release preparations of insulin comprising polyamino acid particles, insulin and one or more preservative agents, and a method of preparing such preparations. |
| 01/08/2004 | US20040005996 Method of producing protein stabilised emulsions comprising the steps of decreasing the pH of a protein solution by the addition of an acidic solution to convert it to a cationic form, heating the solution until the protein is solubilised, |
| 01/08/2004 | US20040005708 For gene therapy, transferring therapeutic genes into cells |
| 01/08/2004 | US20040005684 Targeting proteins to deliver therapeutic or diagnostic reagents |
| 01/08/2004 | US20040005641 Identifying compounds which enhance efficacy and transfer of therapeutic agents; drug delivery; for treating blood, respiratory, tumor and metabolic disorders |
| 01/08/2004 | US20040005598 Comprises nucleotide sequences coding protein upregulated in metastatic prostate cancer (PUMPCn) for diagnosis and treatment of tumors; antiproliferative agents; anticarcinogenic agents |
| 01/08/2004 | US20040005561 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 01/08/2004 | US20040005470 Heparin compositions and methods of making and using the same |
| 01/08/2004 | US20040005363 A biodegradable biopolymer material consists of silk fibroin from domesticated silkworm; silk fibroin from wild silkworm; a composite material comprising silk fibroin from domesticated silkworm and silk fibroin from wild silkworm; or a composite |
| 01/08/2004 | US20040005360 Core-and-shell dosage form or unit in which the core contains API and in which the shell substantially governs the release such as by controlling diffusion of API through the shell. The shell may comprise a release-blocking polymer, and particles |
| 01/08/2004 | US20040005358 Formulation is provided which is capable of releasing vasopeptidase inhibitor, preferably omapatrilat or gemopatrilat, in a manner to provide therapeutically effective NEP inhibitory activity and therapeutically effective ACE |
| 01/08/2004 | US20040005354 Oral trimethobenzamide formulations and methods |
| 01/08/2004 | US20040005337 Dietary supplements for improving kidney function |
| 01/08/2004 | US20040005334 Redirection of cellular immunity by receptor chimeras |
| 01/08/2004 | US20040005309 Targeted therapeutic proteins |
| 01/08/2004 | US20040005305 Nutritional composition for treating an immune condition |
| 01/08/2004 | US20040005302 Use of immunoisolating implantable devices enclosing genetically engineered antigen-producing cells for eliciting immune responses against an antigen in a host. |
| 01/08/2004 | US20040005289 Ophthalmic compositions of lubricating eyes and methods for making and using same |
| 01/08/2004 | US20040005275 Polyoxyethylene glycol, fatty acid mono- and diglyceride ester especially for intranasal administration of, e.g., antiemetics or migraine treating agents |
| 01/08/2004 | DE10226494A1 Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen Film form mucoadhesive dosage forms for administration of cannabis drugs |
| 01/08/2004 | DE10226459A1 Verwendung von Dopamin-Partialagonisten zur Behandlung des Restless Legs Syndroms Use of dopamine partial agonists for the treatment of Restless Legs Syndrome |
| 01/08/2004 | DE10226098A1 Wirkstoff-Trägersystem Drug-carrier system |